Quest Diagnostics 2000 Annual Report Download - page 11

Download and view the complete annual report

Please find page 11 of the 2000 Quest Diagnostics annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 108

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108

9
We constantly seek innovative ways to
enhance patient care and provide value
to our customers. We support the
creativity, courage and persistence that
transform information into knowledge,
and knowledge into insights. We seek
continuous advancement through the
adaptation of existing knowledge as well
as through experimentation, with the
full understanding that we learn from
our failures as well as our successes.
At Quest Diagnostics, our commitment to inno-
vation is backed up by an impressive number of
industry firsts. For example, we were the first
commercial laboratory to offer routine choles-
terol testing back in 1977, first to develop HIV
resistance testing with help from Dr. Merigan’s
team in 1997, first to offer the HercepTest nation-
ally for HER2 testing in 1998, first to offer
high-risk human papillomavirus DNA testing for
inconclusive ThinPrep Pap Tests in 2000. And,
there is much more to come. Rapid-fire
advancements in genomics are driving innova-
tion. We are the leader in gene-based medical
testing with approximately 20% of the market
and a growth rate of more than 25% per year.
To stay on the leading edge of research, we enlist
dozens of “Academic Associates,” like Dr.
Merigan, at leading institutions. Together we apply
new technologies to diagnostic testing and make
them widely available. Nichols Institute is our
world-renowned esoteric testing laboratory and
research and development center.
Gene-based testing promises new information
to improve a doctor’s ability not only to diagnose
disease, but also to predict a patient’s likely
response to a given treatment or predisposition
to disease. In short, our clients are asking for
more than diagnostic data alone. They want
health care insights, drawing upon our vast expe-
rience, our collaborations with others and our
massive database of test information.
Doctors want insights to help them tailor deci-
sions for individual patients: “How will my
patient’s particular viral mutation of HIV respond
to traditional antiviral therapy? Which of my
breast cancer patients are likely candidates for a
promising new drug? How can I find answers to
inconclusive Pap test results?”
The genomics revolution raises the importance
of laboratory-based insights in the drug develop-
ment process. For example, we have compiled a
large database of unusual viral mutations.
Combined with database query tools of a
partner, Structural Bioinformatics Inc., we help
drug companies narrow the field of potential new
leads, speeding new therapies to patients.
Value: Innovation
The genomics
revolution is
changing medicine,
beginning with
diagnostic and
predictive tests.